These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9510627)

  • 1. High dose cytotoxic chemotherapy with peripheral blood stem cell (PBPC) transplantation--malignancy and beyond.
    Siddiqui T
    J Pak Med Assoc; 1997 Nov; 47(11):266-7. PubMed ID: 9510627
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis in various malignancies.
    Efremidis AP; Koumakis G; Filis J; Moraki M; Vassilomanolakis M; Barbounis V; Hatzichristou H; Papanastasiou K; Stamatellou M
    Bone Marrow Transplant; 1996 Apr; 17(4):673-4. PubMed ID: 8722374
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
    Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
    Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of peripheral blood stem cells mobilized with granulocyte colony-stimulating factor with or without prior standard-dose chemotherapy in patients with malignancy.
    Kobayashi N; Kasai M; Masauzi N; Ogasawara M; Kiyama Y; Naohara T; Higa T; Hashino S; Tanaka J; Imamura M
    Jpn J Clin Oncol; 1995 Dec; 25(6):250-7. PubMed ID: 8523821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic colony-stimulating factors and dose intensity.
    Petros WP; Peters WP
    Semin Oncol; 1993 Feb; 20(1):94-9. PubMed ID: 7682727
    [No Abstract]   [Full Text] [Related]  

  • 9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery.
    Remes K; Matinlauri I; Grenman S; Itälä M; Kauppila M; Pelliniemi TT; Salminen E; Vanharanta R; Rajamäki A
    J Hematother; 1997 Feb; 6(1):13-9. PubMed ID: 9112214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis.
    Schots R; Van Riet I; Damiaens S; Flament J; Lacor P; Staelens Y; Steenssens L; van Camp B; De Waele M
    Bone Marrow Transplant; 1996 Apr; 17(4):509-15. PubMed ID: 8722347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy].
    Richel DJ; Baars JW; Wijngaarden MJ; van der Schoot CE; Vlasveld LT; Rodenhuis S
    Ned Tijdschr Geneeskd; 1993 Jan; 137(5):245-50. PubMed ID: 7679478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methods of autologous peripheral blood stem cell (PBSC) mobilization in oncological and hematological patients].
    Fregatova LM; Shavva SA; Platonova GG; Golovacheva AA; Afanas'ev BV
    Vopr Onkol; 1999; 45(4):380-3. PubMed ID: 10532095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y; Akay C; Thomas C
    Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials of granulocyte colony-stimulating factors for treatment of bone marrow depression associated with cancer chemotherapy.
    Lieschke GJ; Morstyn G
    Immunol Ser; 1992; 57():671-93. PubMed ID: 1380312
    [No Abstract]   [Full Text] [Related]  

  • 19. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
    Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
    J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.